Tyra Biosciences, Inc. (TYRA)

NASDAQ: TYRA · Real-Time Price · USD

14.46

-0.25 (-1.70%)

Jan 31, 2025, 4:00 PM EST - Market closed

Tyra Biosciences Employees

Tyra Biosciences had 49 employees as of December 31, 2023. The number of employees increased by 11 or 28.95% compared to the previous year.

Employees

49

Change (1Y)

11

Growth (1Y)

28.95%

Revenue / Employee

n/a

Profits / Employee

-$1,708,980

Market Cap

760.64M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	49	11	28.95%
Dec 31, 2022	38	13	52.00%
Dec 31, 2021	25	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	440,000
Johnson & Johnson	131,900
Thermo Fisher Scientific	122,000
Abbott Laboratories	114,000
AstraZeneca	89,900
Novartis AG	75,883
Merck & Co.	72,000
Novo Nordisk	64,319

Employee Rankings

TYRA News

10 days ago - Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium - PRNewsWire
22 days ago - Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302) - PRNewsWire
2 months ago - Tyra Biosciences to Present at Upcoming Investor Conferences - PRNewsWire
3 months ago - Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights - PRNewsWire
3 months ago - Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301) - PRNewsWire
3 months ago - Why Is Cancer-Focused Tyra Biosciences Stock Falling On Friday? - Benzinga
3 months ago - Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC) - PRNewsWire
3 months ago - Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET - PRNewsWire